Side effects and when to get help

What the main-trial table reports

The trials compared tesamorelin with a dummy shot, called a placebo.

The label table reviewed September 28, 2026 reports problems at the spot where the shot went in. They affected 17 in 100 people on tesamorelin and 6 in 100 on a dummy shot.

These problems, called injection-site reactions, can include redness or itching at that spot.

The same table reports joint pain in 13 in 100 people on tesamorelin, compared with 11 in 100 on the dummy shot.

Muscle aches and swelling in the legs or ankles each affected 6 in 100 on tesamorelin and 2 in 100 on the dummy shot.

These figures describe those study groups. They do not tell you which effect a particular person will have.

Blood sugar needs attention

The September 2026 label says tesamorelin can raise blood sugar.

The trials counted people whose blood-sugar test reached the level used to identify diabetes. That happened in 5 in 100 on tesamorelin and 1 in 100 on the dummy shot.

These figures count high test results; they do not tell us how many people had a confirmed diabetes diagnosis. Ask how blood sugar would be checked before and during treatment.

Allergy: know the help plan

The tesamorelin label says a suspected allergic reaction calls for stopping the medicine and prompt medical attention.

MedlinePlus calls a severe allergic reaction a life-threatening emergency. It can develop within seconds or minutes.

MedlinePlus lists fainting, trouble breathing, and a swollen face or tongue among the signs.

For severe allergy signs, MedlinePlus directs people to an emergency room or to call the local emergency service.

Reporting a problem is separate from care

The Food and Drug Administration (FDA) runs MedWatch, where patients can report medicine problems.

Receiving a report does not prove that a medicine caused the reported problem, according to the FDA.

Ask the clinician how to reach medical help between visits. Keep that answer with the written care plan.